Latest stories on ENSC
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
StockTitan56 · neutralproduct/pr
Ensysce completes enrollment for final phase of PF614-MPAR-102 study
The Fly59 · neutralproduct/pr
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
StockTitan63 · neutralproduct/pr
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
TipRanks38 · neutralgeneral
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
TipRanks42 · neutralgeneral
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences GAAP EPS of -$0.20 beats by $0.30
Seeking Alpha68 · bullishearnings
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
StockTitan56 · neutralearnings
8-K/A - Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
Yahoo Finance63 · neutralm&a
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
InvestorsHub63 · neutralm&a
ENSC’s $77 Million Financing and Cy Biopharma Acquisition Puts Phase 2 Pain Therapy on Fast Track
August 6, 2026
MarketChameleon63 · neutralm&a
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio
TipRanks65 · bullishm&a
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
StockTitan58 · neutralm&a
Ensysce Biosciences, Inc. (ENSC) files 8-K
SEC 8-K50 · neutralgeneral
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development
InvestorsHub67 · bullishgeneral
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study | ENSC Stock News
StockTitan63 · neutralproduct/pr
Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21
Seeking Alpha56 · neutralearnings
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Morningstar55 · neutralearnings